Here, we performed a systematic pan-cancer analysis of PRDX3 across 33 cancers using The Cancer Genome Atlas database, examining its expression patterns, gene alterations and mutations, methylation, subcellular localization, signaling pathways, tumor microenvironment, immune infiltration, and associations with clinical outcomes. Here, PRDX3 is linked to neoplasm.